|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...3839404142434445464748...4950» |
- || naltrexone / Generic mfg.
New P3 trial: WHATIF: Clinical Trial to Reduce Drinking in Women With HIV (clinicaltrials.gov) - Jun 19, 2012
P3, N=240, Recruiting, Sponsor: University of Florida
- Vacc-4x / Bionor
Trial completion: Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant (clinicaltrials.gov) - Jun 18, 2012
P1/2, N=24, Completed, Sponsor: Oslo University Hospital
Enrolling by invitation --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: PLUS: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Francisco
Enrolling by invitation --> Completed N=12 --> 8
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P1 trial: Evaluation of the Bioequivalence of a Combined Formulated Tablet (clinicaltrials.gov) - Jun 17, 2012
P1, N=66, Completed, Sponsor: ViiV Healthcare
- | Isentress (raltegravir) / Merck (MSD)
New P1 trial: A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) (clinicaltrials.gov) - Jun 17, 2012
P1, N=27, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Isentress (raltegravir) / Merck (MSD)
Trial completion: PLUS: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Francisco
N=12 --> 8 Recruiting --> Completed
- | Trial completion: Project HERMITAGE: HIV Prevention in Hospitalized Russian Drinkers (clinicaltrials.gov) - Jun 17, 2012
P3, N=700, Completed, Sponsor: Boston Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- Adherence: RSAD-VIH-11: HIV Disclosure and Medication Adherence, a Pilot Study (clinicaltrials.gov) - Jun 14, 2012
P=N/A, N=120, Enrolling by invitation, Sponsor: Policlinique M
- Adherence: Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women (clinicaltrials.gov) - Jun 14, 2012
P=N/A, N=26, Recruiting, Sponsor: Policlinique M
- rosuvastatin / Generic mfg.
Enrollment change, IO biomarker: Effect of Rosuvastatin on Endothelial Function (clinicaltrials.gov) - Jun 13, 2012
P2/3, N=20, Recruiting, Sponsor: University of Hawaii
Active, not recruiting --> Completed N=50 --> 20
- | Selzentry (maraviroc) / ViiV Healthcare
Enrollment closed: Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels (clinicaltrials.gov) - Jun 13, 2012
P2, N=15, Active, not recruiting, Sponsor: University of Hawaii
N=50 --> 20 Recruiting --> Active, not recruiting
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change: Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection (clinicaltrials.gov) - Jun 12, 2012
P2, N=23, Completed, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting N=52 --> 23
- Enrollment change: UDP: A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM) (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=233, Completed, Sponsor: Centers for Disease Control and Prevention
N=52 --> 23 N=725 --> 233
- Trial completion: MATH: HIV and Fat Accumulation (clinicaltrials.gov) - Jun 11, 2012
P2, N=35, Completed, Sponsor: University of California, Los Angeles
N=725 --> 233 Recruiting --> Completed
- Enrollment change: USHER: Two Approaches to Routine HIV Testing in a Hospital Emergency Department (clinicaltrials.gov) - Jun 9, 2012
P2, N=1651, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed N=2084 --> 1651
- Enrollment change: USHER: Two Approaches to Routine HIV Testing in a Hospital Emergency Department (clinicaltrials.gov) - Jun 9, 2012
P=N/A, N=4855, Completed, Sponsor: Massachusetts General Hospital
N=2084 --> 1651 N=34200 --> 4855
- Dapivirine Vaginal Ring (dapivirine) / International Partnership for Microbicides, J&J
Trial withdrawal: A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa (clinicaltrials.gov) - Jun 7, 2012
P3, N=0, Withdrawn, Sponsor: International Partnership for Microbicides, Inc.
N=34200 --> 4855 Not yet recruiting --> Withdrawn
- Dapivirine Vaginal Ring (dapivirine) / International Partnership for Microbicides, J&J
Trial withdrawal: A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa (clinicaltrials.gov) - Jun 7, 2012
P3, N=0, Withdrawn, Sponsor: International Partnership for Microbicides, Inc.
Not yet recruiting --> Withdrawn Not yet recruiting --> Withdrawn
- Dapivirine Vaginal Ring (dapivirine) / International Partnership for Microbicides, J&J
Enrollment change: A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa (clinicaltrials.gov) - Jun 7, 2012
P3, N=0, Withdrawn, Sponsor: International Partnership for Microbicides, Inc.
Not yet recruiting --> Withdrawn N=3000 --> 0
- Dapivirine Vaginal Ring (dapivirine) / International Partnership for Microbicides, J&J
Enrollment change: A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa (clinicaltrials.gov) - Jun 7, 2012
P3, N=0, Withdrawn, Sponsor: International Partnership for Microbicides, Inc.
N=3000 --> 0 N=3000 --> 0
- ||||||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: GARDEL: Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Na (clinicaltrials.gov) - Jun 7, 2012
P3, N=417, Completed, Sponsor: Pedro Cahn
N=3000 --> 0 Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial termination: UW PIC 330: Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 (clinicaltrials.gov) - Jun 6, 2012
P4, N=10, Terminated, Sponsor: University of Washington
Recruiting --> Completed Recruiting --> Terminated; Enrollment too slow.
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: UW PIC 330: Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 (clinicaltrials.gov) - Jun 6, 2012
P4, N=10, Terminated, Sponsor: University of Washington
Recruiting --> Terminated; Enrollment too slow. N=20 --> 10
- ||||| Prezista (darunavir) / J&J, Intelence (etravirine) / J&J
New P4 trial: POISE: An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (clinicaltrials.gov) - Jun 6, 2012
P4, N=77, Completed, Sponsor: Janssen Inc.
- Clinical: Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=88, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
- | metformin / Generic mfg., pioglitazone / Generic mfg.
New P4 trial: Metabolic Abnormalities in HIV-infected Persons (clinicaltrials.gov) - Jun 4, 2012
P4, N=70, Recruiting, Sponsor: Tufts Medical Center
- Trial completion: TB Px: Improving Latent Tuberculosis (TB) Diagnosis in Thai Children (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=158, Completed, Sponsor: South East Asia Research Collaboration with Hawaii
N=20 --> 10 Not yet recruiting --> Completed
- Trial completion: Family-Based HIV Prevention for Latinos (clinicaltrials.gov) - Jun 4, 2012
P1, N=80, Completed, Sponsor: Rhode Island Hospital
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: Integrase Inhibitor (MK-0518) Viral Decay (clinicaltrials.gov) - Jun 3, 2012
P2, N=24, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
Active, not recruiting --> Completed N=30 --> 24
- Enrollment change: Leukapheresis to Obtain Lymphocytes for Studies on Antiretroviral Naive HIV-infected Patients (clinicaltrials.gov) - Jun 3, 2012
P2, N=220, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
N=30 --> 24 N=80 --> 220
- ||| Fuzeon (enfuvirtide) / Roche
Enrollment change, Adverse events, HEOR: Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration (clinicaltrials.gov) - Jun 3, 2012
P2, N=337, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
N=80 --> 220 N=200 --> 337
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Integrase Inhibitor (MK-0518) Viral Decay (clinicaltrials.gov) - Jun 3, 2012
P2, N=24, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
N=200 --> 337 Not yet recruiting --> Completed
- Trial completion: Leukapheresis to Obtain Lymphocytes for Studies on Antiretroviral Naive HIV-infected Patients (clinicaltrials.gov) - Jun 3, 2012
P2, N=220, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
Not yet recruiting --> Completed Recruiting --> Completed
- |||| Fuzeon (enfuvirtide) / Roche
Trial completion, Adverse events, HEOR: Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration (clinicaltrials.gov) - Jun 3, 2012
P2, N=337, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid (clinicaltrials.gov) - Jun 3, 2012
P2, N=36, Completed, Sponsor: Canadian Immunodeficiency Research Collaborative
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Combination therapy: FLAMINGO: Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (clinicaltrials.gov) - May 30, 2012
P3, N=488, Active, not recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| GSK692342 / GSK, Bill & Melinda Gates Foundation
Enrollment closed, IO biomarker: Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults (clinicaltrials.gov) - May 30, 2012
P2, N=240, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697). (clinicaltrials.gov) - May 30, 2012
P1, N=32, Completed, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- efavirenz / Generic mfg.
Trial completion: Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey (clinicaltrials.gov) - May 30, 2012
P=N/A, N=95, Completed, Sponsor: Policlinique M
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Trial termination: ISS OBS T-003: Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects (clinicaltrials.gov) - May 29, 2012
P=N/A, N=0, Terminated, Sponsor: Istituto Superiore di Sanita
Enrolling by invitation --> Completed Recruiting --> Terminated
- || lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: Kaletra Monotherapy in HIV/HCV Co-infected Subjects (clinicaltrials.gov) - May 27, 2012
P3, N=22, Completed, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Terminated Active, not recruiting --> Completed
- Trial withdrawal: Immune Response to Hepatitis C Virus (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Trial initiation date: Immune Response to Hepatitis C Virus (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: Emory University
Recruiting --> Withdrawn Initiation date: Jan 2005 --> Sep 2005
- Enrollment change: Immune Response to Hepatitis C Virus (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: Emory University
Initiation date: Jan 2005 --> Sep 2005 N=200 --> 0
- trimethoprim/sulfamethoxazole / Generic mfg.
Trial initiation date: Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya (clinicaltrials.gov) - May 21, 2012
P=N/A, N=500, Completed, Sponsor: University of Washington
N=200 --> 0 Initiation date: Nov 2011 --> Feb 2012
- Trial completion, IO biomarker: TIPI: Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults (clinicaltrials.gov) - May 21, 2012
P2, N=45, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Initiation date: Nov 2011 --> Feb 2012 Active, not recruiting --> Completed
- Enrollment change: Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans (clinicaltrials.gov) - May 20, 2012
P=N/A, N=137, Completed, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Active, not recruiting --> Completed N=2000 --> 137
- Trial completion: Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans (clinicaltrials.gov) - May 20, 2012
P=N/A, N=137, Completed, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
N=2000 --> 137 Recruiting --> Completed
- | tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Enrollment change: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - May 16, 2012
P3, N=2900, Recruiting, Sponsor: CONRAD
Recruiting --> Completed N=2200 --> 2900
- | Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
New P2 trial: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - May 16, 2012
P2, N=471, Recruiting, Sponsor: AIDS Clinical Trials Group